Table 1.
Patient, Transplant, and Disease Characteristics
| Measure | All Patients* (N=109) |
|---|---|
| Gender, n (%) | |
|
| |
| Male | 64 (59) |
| 45 (41) | |
|
| |
| Age category in years, n (%) | |
| 18–34 | 60 (55) |
|
| |
| 35–49 | 28 (26) |
|
| |
| ≥ 50 | 21 (19) |
| Ethnicity, n (%) | |
| White | 56 (52) |
|
| |
| Hispanic | 28 (26) |
|
| |
| Black | 15 (14) |
|
| |
| Asian | 8 (7) |
|
| |
| ALL Subtype, n (%) | |
|
| |
| B-cell ALL | 86 (79) |
|
| |
| T-cell ALL | 23 (21) |
| Philadelphia chromosome, n (%) (B-cell ALL patients only) | |
| Negative | 46 (71) |
|
| |
| Positive | 19 (29) |
|
| |
| Cytogenetic risk,** n (%) | |
|
| |
| Poor | 26 (40) |
| Not poor | 39 (60) |
|
| |
| Response before transplant, n (%) | |
| CR 1 | 32 (29) |
|
| |
| CR 2 | 36 (33) |
|
| |
| Other (PIF: n=9; second transplant: n=13) | 41 (38) |
| Minimal residual disease, n (%) (CR 1 and CR 2 patients only) | |
| Yes | 14 (26) |
|
| |
| No | 40 (74) |
|
| |
| WBC at presentation for B-Cell ALL, n (%) | |
|
| |
| ≤ 30 | 38 (68) |
| > 30 | 18 (32) |
|
| |
| WBC at presentation for T-Cell ALL, n (%) | |
| ≤ 100 | 9 (60) |
|
| |
| > 100 | 6 (40) |
|
| |
| Hematopoietic Cell Transplant-Comorbidity Index, n (%) | |
|
| |
| 0–1 | 56 (52) |
| 2–3 | 32 (30) |
| > 3 | 19 (18) |
|
| |
| Cell source, n (%) | |
|
| |
| Peripheral blood | 59 (54) |
| Bone marrow | 50 (46) |
|
| |
| Donor relation, n (%) | |
| Child | 19 (17) |
|
| |
| Parent | 37 (34) |
|
| |
| Sibling | 53 (49) |
| Extramedullary disease, n (%) | |
| Yes | 17 (16) |
|
| |
| No | 91 (84) |
|
| |
| Non-myeloablative regimen, n (%) | |
|
| |
| Yes | 39 (36) |
|
| |
| No | 70 (64) |
| Preparative regimen, n (%) | |
| Melphalan-based | 40 (37) |
|
| |
| Flu/Cy/TBI | 32 (29) |
|
| |
| Busulfan-based | 9 (8) |
|
| |
| TBI-based | 25 (23) |
|
| |
| Other | 3 (3) |
Abbreviations: ALL, acute lymphoblastic leukemia; CR1, patients in first complete remission; CR2, patients in second complete remission; Flu/Cy/TBI, fludarabine/cyclophosphamide/total body irradiation; PIF, primary induction failure.
*
Because of missing data for some covariates, numbers don't add up for a total of 109 patients in all subgroups.
**
Alvarnas JC, Brown PA, Aoun P, et al. Acute Lymphoblastic Leukemia, Version 2.2015. J Natl Compr Canc Netw. 2015;13:1240–1279.